Amyloid imaging: Coming to a PET scanner near you

Annals of Neurology

Volumn 68, Issue 3, 2010, Pages 277-278

  Jagust, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; AMYLOID;

ALZHEIMER DISEASE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN REGION; COMMUNITY HOSPITAL; CYCLOTRON; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG UPTAKE; EDITORIAL; HUMAN; ISOTOPE LABELING; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TEST RETEST RELIABILITY; UNIVERSITY HOSPITAL; WHITE MATTER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC USE; METABOLISM; PROCEDURES; SCINTISCANNING;

ALZHEIMER DISEASE; AMYLOID; FLUORODEOXYGLUCOSE F18; HUMANS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 77956371589     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22144     Document Type: Editorial

References (11)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319. (Pubitemid 38269583)
2. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer's disease and MCI: a phase 2 trial. Ann Neurol 2010;68:319-329.
3. Nelissen N, Van Laere K, Thurfjell L, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251-1259.
4. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66:1837-1844.
5. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-131.
6. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-1153.
7. Furst AJ, Rabinovici GD, Rostomian AH, et al. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease.. Neurobiol Aging (in press). Available at http://dx.doi.org/10.1016/j.neurobiolaging. 2010.03.011. Accessed July 29, 2010.
8. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65:557-568.
9. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med 2010;51:913-920.
10. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-135.
11. Jack CR, Jr.,Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.